Diagnosis of antiphospholipid syndrome (APS) requires the presence of a clinical criterion
(thrombosis and/or pregnancy morbidity), combined with persistently circulating …

This guidance focuses on methodological aspects of lupus anticoagulant (LA) testing, as
well as interpretation of results for clinicians. The main changes in how to test for LA …

Background Lupus anticoagulants (LA) are one laboratory criterion for classification of
antiphospholipid syndrome, with presence of vascular thrombosis and/or pregnancy/fetal …

Abstract VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a
recently described autoinflammatory syndrome characterized by diffuse inflammatory …

There is a laboratory and clinical need to know the impact of direct oral anticoagulants
(DOACs) on diagnostic tests to avoid misinterpretation of results. Although the regulatory …

The term “lupus anticoagulant (LA)” identifies a form of antiphospholipid antibodies (aPLs)
causing prolongation of clotting tests in a phospholipid concentration-dependent manner …

Introduction Lupus anticoagulant (LA) investigation in patients on anticoagulant therapy is
problematic. Rivaroxaban in particular causes significant interference, prolonging both LA …

Snake venoms have evolved primarily to immobilize and kill prey, and consequently, they
contain some of the most potent natural toxins. Part of that armory is a range of hemotoxic …

Abstract Background Direct oral anticoagulants (DOACs) interfere with lupus anticoagulant
(LAC) testing. DOAC‐Stop (D‐S) represents a preanalytical strategy to cope with this issue …

Background Heparins and heparinoids interfere with functional clotting assays used for
lupus anticoagulant (LAC) detection. However, current guidelines for LAC testing do not …